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INTRODUCTION 93
Natural killer (NK) 
100
NK cells are derived from CD34 + precursors, 3, 6 and their development can 101 be stratified to 5 stages, 7 characterized by specific surface receptors and 102 proliferative and functional capacities. 8, 9 CD56 bright NK cells are the minor subset 103 (~10%) of NK cells within peripheral blood. 5 They are characterized by low 104 expression of perforin and high expression of CD94-NKG2A receptors, 7 and a 105 subset of cells retain CD117 (c-Kit) expression.
7, 10 NKG2D, NKp46, CD62L and 106 detectable CD122 are highly expressed. [10] [11] [12] These cells are sources of cytokines 107 reflected by high levels of interferon (IFN)-γ and granulocyte monocyte-colony 108 stimulating factor (GM-CSF). 1, [7] [8] [9] [10] [13] [14] [15] [16] [17] [18] . A functional and phenotypic intermediate 109 populations between CD56 bright and CD56 dim have also been described in healthy 110 donors. 9, 11, 19 NK cell terminal maturation is defined by up-regulation of perforin, 111 CD16, CD57, CD8 and NKp46, and down-regulation of CD94. 7, 11, [15] [16] [17] NK cell 112 development and homeostasis requires interleukin (IL)-15, 20, 21 and in both 113 mouse and human systems NK cells do not develop in the absence of 6 Classical natural killer deficiency (cNKD) is characterized by the absence 115 of both NK cells and their cytotoxic function, [23] [24] [25] [26] [27] whereas functional NK cell 116 deficiency (fNKD) is characterized by normal frequencies of NK cells in 117 peripheral blood with decreased function. 28, 29 There are several immune 118 deficiency diseases that affect NK cell development and/or function. 29 Patients 119 with NKD have increased susceptibility to viral infections, including 120 herpesviruses, varicella zoster, herpes simplex, cytomegalovirus, and human 121 papilloma virus. [23] [24] [25] [26] [27] 30 Severe herpes viral infection with decreased NK cell 122 natural cytotoxicity has been reported in patients with loss-of-function mutations 123 in signal transducer and activator of transcription-(STAT) 1, 31 and recently in 8 124 patients with STAT1 gain of function (GOF) mutations. 32 
125
The STAT family includes seven members: STAT1-4, STAT5a and b, and 126
STAT6.
33 Activation through intracellular domains of cytokine receptors, including 127 those for IFN-α/γ, IL-2, IL-4, 34-36 leads to association with 128 Janus kinase (JAK) family members and recruitment and phosphorylation of 129 STAT proteins. 33, [37] [38] [39] [40] Phosphorylated STAT proteins form homo-or 130 heterodimers and translocate to the nucleus where they bind to consensus 131 sequences in the promoters of target genes 33, 41 . In addition to roles in 132 development and homeostasis, STAT proteins mediate viral defense in NK 133 cells.
42 Upon IL-2 stimulation, pSTAT5 binds two enhancers located in the 5' 134 region of PRF1 promoting its transcription;
43 upon IL-6 and IL-12 stimulation this 135 enhancer is bound by pSTAT1 and pSTAT4 respectively 44, 45 
STAT1 mutations 259
Sequencing of STAT1 identified heterozygous mutations in each patient. 260
In 8 patients, the mutations were in the coiled-coil domain (CCD) and the 261 remainders were in the DNA-binding domain (DBD) ( Table I) . Out of eight 262 discrete mutations, seven have been previously reported; 51, 53, 54 c.983A>G 263
p.H328R is novel. 264
In vitro STAT1 activation was tested in primary patient NK cells 265 representing 5 mutations (3 CCD and 2 DBD) in response to IFN-α. We observed 266 persistent phosphorylation without appropriate dephosphorylation in all patients 267 NK cells when compared to healthy donors (Fig 1, A) . Furthermore, mutations in 268 the DBD had significantly higher levels of activated STAT1 after 120 minutes of 269 stimulation than mutations located in the CCD (Fig 1, B) . Interestingly, we 270 observed that patients with mutations in the DBD tend to have a more severe 271 clinical phenotype than patients with CCD mutations (Table I) . 272
Patients with STAT1 GOF mutations have decreased NK cell cytotoxic 273 function 274
We performed standard Cr 51 release assays using PBMCs from 14 275 patients and healthy donor controls using K562 target cells in the presence and 276 absence of exogenous IL-2. We compared the NK cell cytotoxicity activity from 277 each patient with a representative NK cell cytotoxicity from a pool of 10 healthy 278 donors. NK cells from most patients with CCD mutations had residual cytotoxic 279 function that was partially responsive to IL-2 ( function found in our patients was associated with a demonstrable NK cell 293 phenotype, we performed flow cytometry for NK cell developmental markers, 294 functional NK cell receptors (activating and inhibitory), intracellular cytokines, and 295 lytic granule contents 7, 10, 25, 58 . NK cell subsets were identified as CD56 bright CD3 − 296 or CD56 dim CD3 − (Fig 3, A) . We observed lower NK cell frequencies in STAT1 297 GOF patients (4.0±2.5%) (mean±SD) compared to healthy donors (9.7 ± 2.1%). 298
The frequency of CD56 bright NK cell subset in peripheral blood from patient and 299 control groups was similar. However, patients with STAT1 GOF mutations had a 300 decreased frequency of cells within the CD56 dim NK cell subset (2.631±1.774%) 301 in peripheral blood than healthy donors (9.894%, range 7.25-13.7%) (Fig 3, B) , 302 suggesting impaired terminal maturation or survival of the CD56 dim NK cell 303
subset. 304
In healthy donors, the CD56 dim NK cell subset is characterized by high 305 levels of expression of CD16 and perforin and acquisition of CD57 and CD8. with the CD56 bright subset, including CD94, CD117, CD94, and NKG2A (Fig 3, D  313 and E3, B). While the CD56 bright subset in NK cells from patients with STAT1 314 GOF mutations had higher levels of granzyme B and lower levels of TNF-α (see 315 Fig E3, C) , the CD56 dim subset appears to have impaired terminal maturation. 316
These findings suggest that the CD56 dim subset in STAT1 GOF patients is 317 immature and potentially non-functional. 318
STAT1 GOF mutations lead to decreased perforin expression and cytotoxic 319 capacity in NK cell lines 320
To further delineate the effect of STAT1 dysregulation on NK cell 321 phenotype and function, we modeled two of the DBD mutations (E353K and 322 T385M) in YTS NK cell lines using CRISPR-Cas9 mediated gene editing. While 323 expression of total STAT1 was not affected by either mutation in either cell line 324 (data not shown), both mutant cell lines showed enhanced STAT1 325 phosphorylation in response to IFN-α stimulation compared with WT cells (Fig 4,  326 A). To further elucidate the abnormality seen in the primary cells, we looked at 327 select developmental markers in this cell line. The expression of CD94 and 328 NKG2A was increased in the mutant cell lines compared to WT (Fig 4, B) . 329
Furthermore, we detected decreased perforin expression of YTS STAT1 mutant 330 cell lines compared to WT (Fig 4, B) . To determine whether these phenotypic 331 differences corresponded with an effect on function, we performed Cr 51 release 332 cytotoxicity assays and observed that the cytotoxic capacity of YTS STAT1 333 mutants was decreased more than 4-fold compared with the WT (Fig 4, C) . 334
Similarly, expression of the CCD M202I mutation in a different NK cell line, NK92, 335 led to an analogous functional phenotype (Fig 4, D and see Fig E4) with 336 decreased perforin expression and reduced NK cell cytotoxic function (Fig 4, D) . 337
This phenotype was consistent with our results from primary patient cells, as the 338 effect of CCD mutations was milder than that of the DBD mutations and define 339 the impact of patient-derived mutant STAT1 GOF on NK cell perforin expression 340 and maturation signatures. 341
STAT1 GOF mutations impair STAT5 phosphorylation in NK cells 342
The functional assays were performed in patients with mutations in the 343 CCD (patients 2, 4, 5, 6, 7, and 8) and DBD (patients 11, 15, and 16) . 344
Considering the vital STAT-related role of IL-15 in NK cell development and 345 homeostasis, we evaluated the proliferative capacity of NK cells from STAT1 346 GOF patients in response to IL-15 stimulation. All patients tested had significantly 347 decreased proliferation compared to healthy donors, independent of the affected 348 domain (Fig 5, A) . 349
Significant crosstalk between STAT signaling molecules exists, including 350 antagonistic binding to common enhancer elements. In particular, the competitive 351 binding of STAT3 and STAT5 to a common 5' perforin enhancer has been 352 demonstrated in T lymphocytes, dendritic cells, and cancer cell lines. 18, 43, 59 On 353 other hand, STAT5 induces perforin expression in response to IL-2. 43 To 354 determine whether the delayed dephosphorylation of STAT1 affects the 355 activation of STAT5 and leads to the significantly decreased perforin expression 356 in NK cells from patients with STAT1 GOF mutations, we evaluated STAT5 357 activation after IL-2 stimulation. We observed significantly decreased STAT5 358 activation in response to IL-2 in CD56 dim NK cells from the CCD and DBD 359 mutations (Fig 5, B) . Interestingly, patients with DBD mutations had lower levels 360 of perforin compared with CCD patients (Fig 5, C) . The lower levels of 361 phosphorylated STAT5 in DBD patients after 30 minutes of stimulation 362 corresponds with the degree of impairment of perforin expression in STAT1 GOF 363 NK cells (Fig 5, B and C) . 364
To determine whether low NK cell proliferation with IL-15 stimulation and 365 low STAT5 activation in response to IL-2 was due to abnormal IL-2 and IL-15 366 receptor expression, we measured their expression by flow cytometry. We found 367 normal receptor expression for IL-2 and IL-15 in healthy donors and affected 368 subjects (data not shown). Therefore, the degree of impairment of NK cell 369 proliferation and perforin expression in STAT1 GOF NK cells tracks with the 370 degree of impairment in STAT5 activation. 371
Ruxolitinib treatment restores perforin expression and cytotoxicity in 372
CD56 dim NK cells from STAT1 GOF patients 373
Recently, three studies reported the efficacy of JAK1/2 pathway inhibition 374 by ruxolitinib in patients with STAT1 GOF mutations. Constitutive hyper-375 phosphorylation of STAT1 in these patients was inhibited while STAT3 376 phosphorylation was not affected. Importantly, ruxolitinib treatment led to 377 improvement of CMC and autoimmunity. [60] [61] [62] We sought to determine whether 378 ruxolitinib affected the phenotype of NK cells from patients with STAT1 GOF 379 mutations. We evaluated the NK cell phenotype and function from three patients 380 (3, 9, and 11) before and during oral ruxolitinb treatment. We observed higher 381 levels of CD56 dim Perforin + NK cells after treatment with restoration of perforin 382 expression on CD56 dim NK cells during ruxolitinib treatment (Fig 6, A and see Fig  383   E5 , A), accompanied by a 5-fold increase in NK cytotoxicity in response to IL-2 384 in patient 9 and a 2-fold increase in patient 11 (Fig 6, B) . In addition, the ADCC 385 from patient 11 showed a 2-fold increase (see Fig E5, C) . Increased perforin 386 expression accompanied improved NK cytotoxic function. We did not observe an 387 increase in NK cytotoxicity in patient 3 likely do to the short duration of treatment 388 when the assay was performed (Fig E5, B) . Patient 9 and 11 had been on 389 ruxolitinib for at least 3 months when the post-ruxolitinib assays were performed, 390 whereas, Patient 3 was treated for only 2 weeks. Perforin restoration is 391 immediate while improvement in cytotoxicity comes with a longer duration of 392 therapy. Weinacht et al 62 reported a patient with clinical and laboratory 393 improvement after a year on ruxolitinib treatment. Taking our experiences 394
together, it appears at least 3 months of therapy with Ruxolitinib is needed to 395 demonstrate improvement in function. 396
Interestingly, while the expression of perforin increased, CD16, CD8, and 397 CD57 expression was not affected (see Fig E5, D) . Despite the dramatic 398 increase in perforin and improved NK cell cytotoxicity, the course of the fungal 399 infection was so advanced in patient 11 when treatment was started that her 400 disease was not ameliorated and she eventually died. However, on acyclovir 401
prophylaxis, she did not have any breakthrough herpes infections. Patient 9 402 experienced significant improvement in his enteropathy and chronic norovirus. (Fig 6, C) , which also corresponds with low perforin 410 expression in pre-treatment samples. After ruxolitinib treatment, we observed 411 higher levels of STAT5 activation in post-treatment sample from patient 9 and 11 412 (Fig 6, D) . These results demonstrate that decreased activation of STAT1 413 through JAK inhibition affects the activation of STAT5 and, in turn, perforin 414 expression. To compliment the studies on the in vivo effects of ruxolitinib 415 treatment over perforin expression, we incubated PBMCs isolated from another 416 patient (Pt 13) for 48 hours with 1 µM of ruxolitinib. Perforin expression was 417 partially restored in CD56 dim NK cells (Fig 6, E) ; whereas, the levels of perforin 418 observed in CD56 dim NK cells from healthy donors were not affected. Similar 419 results were observed using the STAT1 GOF NK cell line (see Fig E5, 
